Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

November 05, 2018

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

October 22, 2018

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

News Daily News

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Yael L. Maxwell

June 15, 2018

Alirocumab Price Slashed in Deal With Express Scripts

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

News Daily News

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

April 18, 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

March 10, 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

March 05, 2018

PCSK9 Inhibitors - Are They Worth The Money?

Presentation Controversies and Advances 2017

PCSK9 Inhibitors - Are They Worth The Money?

Presenter: Michael J. Blaha

November 16, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.